Wall Street analysts predict that Horizon Pharma PLC (NASDAQ:HZNP) will announce $278.03 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Horizon Pharma’s earnings. The highest sales estimate is $283.79 million and the lowest is $274.10 million. Horizon Pharma reported sales of $289.51 million in the same quarter last year, which would suggest a negative year over year growth rate of 4%. The firm is expected to announce its next earnings report on Monday, August 6th.
On average, analysts expect that Horizon Pharma will report full-year sales of $1.17 billion for the current fiscal year, with estimates ranging from $1.17 billion to $1.18 billion. For the next year, analysts forecast that the business will post sales of $1.28 billion per share, with estimates ranging from $1.23 billion to $1.33 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Wednesday, May 9th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.08). The company had revenue of $223.88 million during the quarter, compared to analysts’ expectations of $232.05 million. Horizon Pharma had a negative net margin of 45.06% and a positive return on equity of 16.97%. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.21 earnings per share.
HZNP has been the topic of a number of recent research reports. ValuEngine upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Saturday. BidaskClub upgraded shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 3rd. Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 price target on shares of Horizon Pharma in a research report on Wednesday, March 14th. Morgan Stanley increased their price target on shares of Horizon Pharma from $14.00 to $16.00 and gave the company an “equal weight” rating in a research report on Friday, March 2nd. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $22.00 price target on shares of Horizon Pharma in a research report on Thursday, March 1st. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $19.20.
HZNP traded up $0.07 on Wednesday, reaching $16.40. The company had a trading volume of 3,022,153 shares, compared to its average volume of 1,881,441. The company has a market capitalization of $2.67 billion, a P/E ratio of 13.90, a P/E/G ratio of 0.96 and a beta of 1.29. The company has a debt-to-equity ratio of 2.17, a current ratio of 1.56 and a quick ratio of 1.50. Horizon Pharma has a 52-week low of $9.90 and a 52-week high of $16.50.
In other Horizon Pharma news, EVP Brian K. Beeler sold 17,931 shares of the stock in a transaction that occurred on Friday, May 25th. The shares were sold at an average price of $16.11, for a total transaction of $288,868.41. Following the transaction, the executive vice president now directly owns 110,524 shares in the company, valued at $1,780,541.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.90% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the business. Trexquant Investment LP purchased a new position in Horizon Pharma during the first quarter valued at $2,008,000. American Century Companies Inc. lifted its position in Horizon Pharma by 158.5% during the first quarter. American Century Companies Inc. now owns 706,775 shares of the biopharmaceutical company’s stock valued at $10,036,000 after buying an additional 433,359 shares during the period. Systematic Financial Management LP purchased a new position in Horizon Pharma during the first quarter valued at $1,428,000. James Investment Research Inc. purchased a new position in Horizon Pharma during the fourth quarter valued at $1,920,000. Finally, Swiss National Bank raised its position in shares of Horizon Pharma by 2.9% in the 4th quarter. Swiss National Bank now owns 278,156 shares of the biopharmaceutical company’s stock worth $4,061,000 after purchasing an additional 7,800 shares during the last quarter. 84.33% of the stock is owned by institutional investors and hedge funds.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.